ROSWELL PARK CANCER INSTITUTE

🇺🇸United States

Country: 🇺🇸United States

Ownership: -

Employees: -

Market Cap: -

Website

Clinical Trials

Cholecalciferol and Flu Vaccine in Treating Healthy Participants

Not Applicable

Terminated

Conditions: Healthy, no Evidence of Disease

Interventions: Dietary Supplement: cholecalciferol
Other: questionnaire administration
Biological: trivalent influenza vaccine

First Posted Date: 2012-03-23

Last Posted Date: 2020-03-10

Lead Sponsor: Roswell Park Cancer Institute

Target Recruit Count: 11

Registration Number: NCT01561989

Locations: 🇺🇸
Roswell Park Cancer Institute, Buffalo, New York, United States

Mechanical Stimulation in Preventing Bone Density Loss in Patients Undergoing Donor Stem Cell Transplant

Not Applicable

Withdrawn

Conditions: Adult Acute Myeloid Leukemia in Remission
Extranodal Marginal Zone B-cell Lymphoma of Mucosa-associated Lymphoid Tissue
Myelodysplastic/Myeloproliferative Neoplasm, Unclassifiable
Nodal Marginal Zone B-cell Lymphoma
Noncontiguous Stage II Adult Burkitt Lymphoma
Noncontiguous Stage II Adult Diffuse Large Cell Lymphoma
Noncontiguous Stage II Adult Diffuse Mixed Cell Lymphoma
Noncontiguous Stage II Adult Immunoblastic Large Cell Lymphoma
Adult Acute Myeloid Leukemia With Inv(16)(p13;q22)
Adult Acute Myeloid Leukemia With t(15;17)(q22;q12)

Interventions: Procedure: management of therapy complications
Procedure: musculoskeletal complications management/prevention

First Posted Date: 2012-03-20

Last Posted Date: 2012-07-09

Lead Sponsor: Roswell Park Cancer Institute

Registration Number: NCT01558778

Trebananib With or Without Low-Dose Cytarabine in Treating Patients With Acute Myeloid Leukemia

Phase 1

Completed

Conditions: Adult Acute Megakaryoblastic Leukemia (M7)
Adult Acute Minimally Differentiated Myeloid Leukemia (M0)
Adult Acute Myeloid Leukemia With 11q23 (MLL) Abnormalities
Adult Acute Monocytic Leukemia (M5b)
Adult Acute Myeloblastic Leukemia With Maturation (M2)
Adult Acute Myeloid Leukemia With t(16;16)(p13;q22)
Adult Acute Myeloid Leukemia With Inv(16)(p13;q22)
Adult Erythroleukemia (M6a)
Adult Acute Myeloblastic Leukemia Without Maturation (M1)
Adult Acute Myeloid Leukemia With t(8;21)(q22;q22)

Interventions: Biological: trebananib
Other: laboratory biomarker analysis
Drug: cytarabine
Other: pharmacological study

First Posted Date: 2012-03-15

Last Posted Date: 2022-09-13

Lead Sponsor: Roswell Park Cancer Institute

Target Recruit Count: 24

Registration Number: NCT01555268

Locations: 🇺🇸
Roswell Park Cancer Institute, Buffalo, New York, United States
🇺🇸
University of Rochester, Rochester, New York, United States

Eltrombopag Olamine in Treating Patients With Relapsed/Refractory Acute Myeloid Leukemia

Phase 1

Terminated

Conditions: Adult Acute Myeloid Leukemia With Inv(16)(p13;q22)
Adult Acute Myeloid Leukemia With t(8;21)(q22;q22)
Adult Acute Eosinophilic Leukemia
Adult Acute Myeloblastic Leukemia Without Maturation (M1)
Adult Acute Myeloid Leukemia With t(16;16)(p13;q22)
Adult Erythroleukemia (M6a)
Recurrent Adult Acute Myeloid Leukemia
Adult Acute Megakaryoblastic Leukemia (M7)
Adult Acute Myeloblastic Leukemia With Maturation (M2)
Adult Acute Myeloid Leukemia With Del(5q)

Interventions: Drug: eltrombopag olamine
Procedure: standard follow-up care

First Posted Date: 2012-03-09

Last Posted Date: 2022-07-22

Lead Sponsor: Roswell Park Cancer Institute

Target Recruit Count: 10

Registration Number: NCT01550185

Locations: 🇺🇸
Roswell Park Cancer Institute, Buffalo, New York, United States
🇺🇸
Emory University, Winship Cancer Institute, Atlanta, Georgia, United States

Chemokine-Modulatory Regimen for Recurrent Resectable Colorectal Cancer

Phase 1

Terminated

Conditions: Colorectal Cancer
Colorectal Tumors
Colorectal Carcinoma
Neoplasms, Colorectal

Interventions: Drug: Chemokin Modulatory Regimen (10 MU/m2)
Drug: Chemokin Modulatory Regimen (5 MU/m2)
Drug: Chemokin Modulatory Regimen (20 MU/m2)

First Posted Date: 2012-03-06

Last Posted Date: 2023-10-27

Lead Sponsor: Roswell Park Cancer Institute

Target Recruit Count: 15

Registration Number: NCT01545141

Locations: 🇺🇸
UPMC Hillman Cancer Center, Pittsburgh, Pennsylvania, United States

PI3K Inhibitor BKM120 and Docetaxel in Treating Patients With Advanced Solid Tumor That is Locally Advanced, Cannot Be Removed By Surgery, or Metastatic

Phase 1

Completed

Conditions: Unspecified Adult Solid Tumor, Protocol Specific

Interventions: Drug: PI3K inhibitor BKM120
Drug: docetaxel
Other: pharmacological study
Other: questionnaire administration
Other: laboratory biomarker analysis

First Posted Date: 2012-02-28

Last Posted Date: 2022-07-22

Lead Sponsor: Roswell Park Cancer Institute

Target Recruit Count: 38

Registration Number: NCT01540253

Locations: 🇺🇸
Roswell Park Cancer Institute, Buffalo, New York, United States

Ofatumumab and Bortezomib in Treating Patients With Previously Untreated Waldenstrom Macroglobulinemia

Phase 2

Terminated

Conditions: Waldenström Macroglobulinemia

Interventions: Biological: ofatumumab
Drug: bortezomib
Other: laboratory biomarker analysis

First Posted Date: 2012-02-20

Last Posted Date: 2016-06-10

Lead Sponsor: Roswell Park Cancer Institute

Target Recruit Count: 3

Registration Number: NCT01536067

Locations: 🇺🇸
Roswell Park Cancer Institute, Buffalo, New York, United States
🇺🇸
Weill Cornell Medical College, New York, New York, United States

Sirolimus and Vaccine Therapy in Treating Patients With Stage II-IV Ovarian Epithelial, Fallopian Tube, or Primary Peritoneal Cavity Cancer

Phase 1

Completed

Conditions: Recurrent Fallopian Tube Cancer
Recurrent Ovarian Epithelial Cancer
Recurrent Primary Peritoneal Cavity Cancer
Stage IIA Fallopian Tube Cancer
Stage IIA Ovarian Epithelial Cancer
Stage IIA Primary Peritoneal Cavity Cancer
Stage IIB Fallopian Tube Cancer
Stage IIB Ovarian Epithelial Cancer
Stage IIB Primary Peritoneal Cavity Cancer
Stage IIC Fallopian Tube Cancer

Interventions: Biological: ALVAC(2)-NY-ESO-1 (M)/TRICOM vaccine
Drug: sirolimus
Other: laboratory biomarker analysis
Biological: sargramostim

First Posted Date: 2012-02-20

Last Posted Date: 2020-03-27

Lead Sponsor: Roswell Park Cancer Institute

Target Recruit Count: 7

Registration Number: NCT01536054

Locations: 🇺🇸
Roswell Park Cancer Institute, Buffalo, New York, United States

Axitinib in Treating Patients With Melanoma That is Metastatic or Cannot Be Removed by Surgery

Phase 2

Terminated

Conditions: Metastatic Intraocular Melanoma
Recurrent Intraocular Melanoma
Stage IIIA Intraocular Melanoma
Stage IIIB Intraocular Melanoma
Stage IIIC Intraocular Melanoma
Stage IV Intraocular Melanoma
Stage IIIB Melanoma
Extraocular Extension Melanoma
Recurrent Melanoma
Stage IIIC Melanoma

Interventions: Drug: axitinib
Other: laboratory biomarker analysis

First Posted Date: 2012-02-16

Last Posted Date: 2018-05-09

Lead Sponsor: Roswell Park Cancer Institute

Target Recruit Count: 25

Registration Number: NCT01533948

Locations: 🇺🇸
Roswell Park Cancer Institute, Buffalo, New York, United States

Autofluorescence Detection of Oral Malignancies and Database and Biospecimen Collection to Identify Biomarkers of Head and Neck Tumor Progression

Completed

Conditions: Oral Cancer

First Posted Date: 2012-02-13

Last Posted Date: 2023-04-28

Lead Sponsor: Roswell Park Cancer Institute

Target Recruit Count: 240

Registration Number: NCT01531881

Locations: 🇺🇸
Roswell Park Cancer Institute, Buffalo, New York, United States

© Copyright 2024. All Rights Reserved by MedPath

Home Terms & Conditions Privacy Policy